A Salute to Our Founding Editor-in-Chief Bramah N. Singh, MD, DPhil, DSc, FRCP

  title={A Salute to Our Founding Editor-in-Chief Bramah N. Singh, MD, DPhil, DSc, FRCP},
  author={Robert A. Kloner},
  journal={Journal of Cardiovascular Pharmacology and Therapeutics},
  pages={154 - 156}
  • R. Kloner
  • Published 1 September 2009
  • Medicine
  • Journal of Cardiovascular Pharmacology and Therapeutics
D r Bramah N. Singh, MD, DPhil, DSc, FRCP, is one of the world’s leading experts on arrhythmias and antiarrhythmic pharmacology. He has had a long and distinguished career in clinical and experimental cardiology and pharmacology spanning several continents and 5 decades. Dr Singh was born on March 3, 1938, in the Fiji Islands. He received his MD from the University of Otago in New Zealand in 1963, and his postgraduate training included a rotating internship at Auckland and Green Lane Hospitals… 
1 Citations
Bramah N. Singh, MD, DPhil, DSc: A Tribute
  • G. Naccarelli
  • Medicine
    Journal of cardiovascular pharmacology and therapeutics
  • 2015


Why a New Journal in Cardiovascular Pharmacology and Therapeutics?
  • B. Singh
  • Biology, Medicine
    Journal of cardiovascular pharmacology and therapeutics
  • 1996
During the 1950s and the decades that followed witnessed what clearly has been a revolution in the synthesis and characterization of numerous and novel classes of drugs that have been shown to be effective in the treatment of diseases of the heart and circulation.
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Dronedarone was significantly more effective than placebo in maintaining sinus rhythm and in reducing the ventricular rate during recurrence of arrhythmia.
Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
The prevention of reinduction of VT/VF by intravenous sotalol and suppression of spontaneously occurring arrhythmias by the oral drug were both predictive of long-term drug efficacy.
Prognosis in unstable angina.
Patients with persisting angina after the first 24 hours and those without a previous history of myocardial ischaemia were more likely to develop aMyocardial infarct or to die in hospital, and long-term mortality was found to rise with increasing coronary prognostic index.
The effect of amiodarone, a new anti‐anginal drug, on cardiac muscle
It was concluded that amiodarone had effects on cardiac action potentials similar to those which occur after thyroidectomy.
Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone.
The electrophysiological effects of dronedarone are similar to those of AM but more potent, despite deletion of iodine from its molecular structure, a finding of importance for the development of future class III antiarrhythmic compounds.
The Effect of Delay in Propranolol Administration on Reduction of Myocardial Infarct Size After Experimental Coronary Artery Occlusion in Dogs
The data in these studies indicate that the beneficial effect of propranolol on GIS varies inversely with the delay in drug administration after LAD occlusion, and that no effect is apparent when proPRanolol infusion is begun 6 hours after Occlusion.